Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27145561 | 0.79 | TRPM5 (0.41) | TRPM5HTR1AAADATACHECHRNB2 | |
| SCHEMBL27146256 | 0.79 | TRPM5 (0.41) | TRPM5HTR1AAADATACHECHRNB2 | |
| SCHEMBL7483010 | 0.78 | HTR6 (0.41) | TRPM5HTR1AAADATACHECHRNB2 | |
| SCHEMBL5304917 | 0.78 | HTR1A (0.39) | HTR1AACHECHRNB2CHRNA4HTR2A | |
| SCHEMBL1180151 | 0.77 | OPRM1 (0.47) | HTR1AAADATACHEDRD2HTR2A | |
| SCHEMBL30666589 | 0.77 | MEN1 (0.31) | KMT2A | |
| SCHEMBL30082461 | 0.77 | MEN1 (0.31) | KMT2A | |
| SCHEMBL5680208 | 0.75 | TRPM5 (0.38) | TRPM5HTR1AAADATACHECHRNB2 | |
| SCHEMBL22714298 | 0.75 | TRPM5 (0.48) | TRPM5HTR1AAADATACHECHRNB2 | |
| SCHEMBL5680209 | 0.75 | TRPM5 (0.38) | TRPM5HTR1AAADATACHECHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1609785-B1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | ASTELLAS PHARMA INC (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-7977466-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-1980560-B1 | C-glycoside derivatives for the treatment of diabetes | ASTELLAS PHARMA INC (JP) | 2011-05-25 | — | — | EP | disclosed |
| CN-1802366-B | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC | 2010-12-22 | — | — | CN | disclosed |
| US-7772407-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-1980560-A2 | C-glycoside derivatives for the treatment of diabetes | Astellas Pharma Inc. (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7202350-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-04-10 | — | — | US | disclosed |
| CN-1802366-A | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC (JP) | 2006-07-12 | — | — | CN | disclosed |
| US-20060122126-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1609785-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | Astellas Pharma Inc. (JP) | 2005-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | SLC5A1, SLC5A2, SLC2A1 | TRPM5 3561/4885HTR1A 4160/4885AADAT 2991/4885 |
| US-20060122126-A1 | C-glycoside derivatives and salts thereof | SLC5A1, SLC5A2, SLC2A1 | TRPM5 3561/4885HTR1A 4160/4885AADAT 2991/4885 |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | SLC5A1, SLC5A2, SLC2A1 | TRPM5 3561/4885HTR1A 4160/4885AADAT 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.